ATE415173T1 - Pan dr-bindeproteinen zur erhöhung der immunantwort - Google Patents

Pan dr-bindeproteinen zur erhöhung der immunantwort

Info

Publication number
ATE415173T1
ATE415173T1 AT94929801T AT94929801T ATE415173T1 AT E415173 T1 ATE415173 T1 AT E415173T1 AT 94929801 T AT94929801 T AT 94929801T AT 94929801 T AT94929801 T AT 94929801T AT E415173 T1 ATE415173 T1 AT E415173T1
Authority
AT
Austria
Prior art keywords
peptides
pan
increase
immune response
binding proteins
Prior art date
Application number
AT94929801T
Other languages
English (en)
Inventor
Alessandro Sette
Federico C A Gaeta
Howard M Grey
John Sidney
Jerrery L Alexander
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Application granted granted Critical
Publication of ATE415173T1 publication Critical patent/ATE415173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94929801T 1993-09-14 1994-09-14 Pan dr-bindeproteinen zur erhöhung der immunantwort ATE415173T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12110193A 1993-09-14 1993-09-14

Publications (1)

Publication Number Publication Date
ATE415173T1 true ATE415173T1 (de) 2008-12-15

Family

ID=22394559

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929801T ATE415173T1 (de) 1993-09-14 1994-09-14 Pan dr-bindeproteinen zur erhöhung der immunantwort

Country Status (11)

Country Link
US (2) US5736142A (de)
EP (1) EP0735893B1 (de)
JP (1) JP3926839B2 (de)
CN (1) CN1135181A (de)
AT (1) ATE415173T1 (de)
AU (1) AU698962B2 (de)
DE (1) DE69435171D1 (de)
DK (1) DK0735893T3 (de)
ES (1) ES2318848T3 (de)
PT (1) PT735893E (de)
WO (1) WO1995007707A1 (de)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
WO2003040165A2 (en) 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US20050049197A1 (en) * 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
EP0792157A4 (de) * 1994-09-30 1999-12-01 Anergen Inc Herstellung von mhc-peptid-komplexen
GB9509844D0 (en) * 1995-05-16 1995-07-12 Cancer Res Campaign Tech Screening for inhibitors of TCR-MHC interactions
AU1582797A (en) * 1996-01-24 1997-08-20 Epimmune, Inc. Induction of immune response against desired determinants
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
NZ332347A (en) 1996-06-07 2000-05-26 Zeneca Ltd Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues
EP2009018A3 (de) 1996-06-11 2009-03-18 Northern Sydney and Central Coast Area Health Service T-Zellenantigen-Rezeptopeptide
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
US6562345B1 (en) * 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
ES2371432T3 (es) * 1998-05-13 2012-01-02 Epimmune Inc. Vectores de expresión para estimular una respuesta inmune y procedimientos de uso de los mismos.
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
ES2326146T3 (es) 1998-06-17 2009-10-01 Idm Pharma, Inc. Peptidos de union a hla y sus usos.
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
SI1117421T1 (en) * 1998-10-05 2004-12-31 Pharamexa A/S Methods for therapeutic vaccination
EE200100552A (et) 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
EP1225907A4 (de) * 1999-10-05 2005-06-22 Epimmune Inc Induktion zellulärer immunantworten gegen humanes immundefiziens virus-1 (hiv-1) mittels peptid- und nukleinsäureverbindungen
EP2177534A3 (de) 1999-11-18 2010-07-14 Pharmexa Inc. Heteroklitische Analoga von Klasse-i Epitopen
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20040037843A1 (en) * 1999-12-21 2004-02-26 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
HRP20020721B1 (en) * 2000-02-21 2012-04-30 H. Lundbeck A/S Novel method for down-regulation of amyloid
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1652856A1 (de) * 2000-08-09 2006-05-03 The Regents of The University of California San Diego Stressproteine-abgeleitete Peptide und Verfahren zu deren Verwendung
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
EP2022797A3 (de) 2000-08-28 2011-11-09 Agensys, Inc. Nukleinsäure und entsprechendes Protein mit der Bezeichnung 85P1B3 für die Behandlung und den Nachweis von Krebs
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
EP1573024A4 (de) 2001-04-10 2007-08-29 Agensys Inc Nukleinsäuren und diesen entprechende, für die behandlung und den nachweis verschiedener krebserkrankungen geeignete proteine
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP1395276A4 (de) * 2001-05-15 2004-12-29 Ludwig Inst Cancer Res Struktur-modifizierte peptide und ihre verwendungen
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003277865B2 (en) * 2002-06-25 2008-08-21 City Of Hope Adjuvant-free peptide vaccine
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
AU2002352976B2 (en) 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
CA2505870A1 (en) * 2002-12-11 2004-06-24 Soren Mouritsen Targeting single epitopes
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050118669A (ko) 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
CA2860151A1 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
SI1620456T1 (sl) 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
AU2004263823B2 (en) 2003-05-30 2008-09-18 Agensys, Inc. Prostate stem cell antigen (PSCA) variants and subsequences thereof
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
RU2381234C2 (ru) 2004-05-28 2010-02-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками psca
CA2566506A1 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2005120563A2 (en) * 2004-06-04 2005-12-22 Pharmexa Inc. Induction of an immune response against streptococcus pneumoniae polysaccharides
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
EP1838348B1 (de) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
KR100646313B1 (ko) 2004-12-31 2006-11-14 강원대학교산학협력단 알러지 질환 예방 및 치료용 펩티드 또는 그의 염 및 이를함유한 의약 조성물
EP3300739A3 (de) 2005-03-31 2018-07-18 Agensys, Inc. An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
ES2310072B1 (es) 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
WO2007079448A2 (en) 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
US20090036653A1 (en) * 2006-04-13 2009-02-05 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
JP2009536157A (ja) * 2006-04-13 2009-10-08 ペプチミューン，インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2023952B1 (de) 2006-05-18 2015-07-15 Epimmune Inc. Induktion von immunreaktionen auf das influenzavirus mithilfe von polypepitd- und nukleinsäure-zusammensetzungen
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
WO2008017517A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
NZ575388A (en) 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8440185B2 (en) * 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2586458B1 (de) * 2006-12-27 2016-08-24 The Johns Hopkins University Zusammensetzungen und verfahren zur behandlung von entzündungs- und autoimmunerkrankungen
LT3067066T (lt) 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US20100183658A1 (en) * 2007-03-30 2010-07-22 The Brigham And Women's Hospital, Inc. Novel Compounds for Enhancing MHC Class II Therapies
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
CA2686817A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
AP3467A (en) * 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP3085707B1 (de) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr-bindende peptide und deren anwendungen
US20090169549A1 (en) * 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
WO2009128948A1 (en) * 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
US9764012B2 (en) * 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
ES2731343T3 (es) 2009-05-19 2019-11-15 Univ Miami Composiciones, kits y métodos para presentación de antígenos in vitro, evaluación de eficacia de vacunas y evaluación de la inmunotoxicidad de productos biológicos y fármacos
EP2473523A2 (de) 2009-08-31 2012-07-11 Amplimmune, Inc. Verfahren und zusammensetzungen zur hemmung von transplantatabstossung
WO2011066048A1 (en) 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
CA2851917A1 (en) 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2908851A1 (de) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Verfahren und zusammensetzungen zur krebsbehandlung
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP3028048B1 (de) 2013-07-31 2018-09-26 BioVentures, LLC Zusammensetzungen zur behandlung und prävention von krebs durch anzielung von mit tumoren assoziierten kohlehydrat-antigenen
EP3470081A1 (de) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
TW201622743A (zh) 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
US10111948B2 (en) 2014-04-25 2018-10-30 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
EP3800199B1 (de) 2015-05-05 2024-08-21 The Regents of The University of California H3.3-ctl-peptide und verwendungen davon
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EA201890148A1 (ru) 2015-06-29 2018-05-31 Озе Иммьюнотерапьютикс Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
EP3452507B1 (de) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau-immuntherapie
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
CN109153704A (zh) 2016-05-02 2019-01-04 斯克里普斯研究学院 与hiv-1免疫原相关的组合物和方法
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3606550A2 (de) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Proteinantigene und verwendungen davon
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
IL274130B2 (en) 2017-11-01 2025-08-01 Scripps Research Inst Novel scaffolded hiv-1 vaccine immunogens
MX2020005454A (es) 2017-11-27 2020-08-27 Ose Immunotherapeutics Tratamiento de cancer mejorado.
KR20240134250A (ko) 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
CN109748952B (zh) * 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
AU2019285048B2 (en) 2018-06-13 2023-06-08 The Scripps Research Institute Nanoparticle vaccines with novel structural components
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
AU2020207087A1 (en) 2019-01-12 2021-08-12 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
WO2021228853A1 (en) 2020-05-11 2021-11-18 Ose Immunotherapeutics Vaccine against sars-cov virus
AU2021276401A1 (en) 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
CN116472055A (zh) 2020-08-07 2023-07-21 欧萨尔普罗席纳有限公司 治疗阿尔兹海默氏病的多表位疫苗
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CA3248183A1 (en) 2022-04-14 2023-10-19 The Hospital For Sick Children PFCSP-BASED IMMUNOGENS AND ASSOCIATED COMPOSITION AND METHODS
AU2024341632A1 (en) 2023-09-15 2026-04-23 Prothena Biosciences Limited Compositions and methods of reducing immunogenicity and improving stability of antibodies
EP4780844A1 (de) 2023-09-22 2026-07-29 Regeneron Pharmaceuticals, Inc. Verfahren zur gewinnung von an eine peptid-mhc-schnittstelle bindenden antikörpermolekülen
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5336758A (en) * 1990-03-09 1994-08-09 The United States Of America As Represented By The Department Of Health And Human Services Peptides stimulating cytotoxic T cells immune to HIV RT
WO1992002543A1 (en) * 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
US5679640A (en) 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
DE69231621T2 (de) * 1991-08-26 2001-05-31 Epimmune, Inc. Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons
WO1993005011A1 (en) * 1991-08-29 1993-03-18 Sandoz Ltd. Novel immunosuppressants
SG49008A1 (en) 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same

Also Published As

Publication number Publication date
US7202351B1 (en) 2007-04-10
AU698962B2 (en) 1998-11-12
DE69435171D1 (de) 2009-01-08
EP0735893A4 (de) 1998-02-04
ES2318848T3 (es) 2009-05-01
EP0735893B1 (de) 2008-11-26
WO1995007707A1 (en) 1995-03-23
EP0735893A1 (de) 1996-10-09
JP3926839B2 (ja) 2007-06-06
CN1135181A (zh) 1996-11-06
PT735893E (pt) 2009-03-06
AU7873694A (en) 1995-04-03
JPH09505559A (ja) 1997-06-03
US5736142A (en) 1998-04-07
DK0735893T3 (da) 2009-03-09

Similar Documents

Publication Publication Date Title
DE69435171D1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
LU92488I2 (fr) Dimethyl fumarate
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
DK0503648T3 (da) CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
RU94046424A (ru) Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69726426D1 (de) Unterdrückung von immunantwort durch hemmung von cathepsin s
DE69430868D1 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
IL92629A0 (en) Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
WO1993019178A3 (en) Peptides useful for inducing tolerance
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
RU99107658A (ru) Применение белков в качестве агентов против аутоиммунных заболеваний
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
WO1991003226A3 (en) Pharmaceutical compositions containing aromatic polymers and therapeutic methods using the same
CA2187329A1 (en) Pharmaceutical formulations for treating dust mite allergy
Yin et al. Lactoferrin protects against concanavalin A‐induced liver injury in mice
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0735893

Country of ref document: EP